细针穿刺联合分子生物标志物在甲状腺结节诊断中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2013.11.011

摘要/Abstract

摘要： 甲状腺结节常通过触诊、血清甲状腺激素、高频超声等检查来进行评估，在诊断困难时进行细针抽吸穿刺活检(FNA)来区分结节的良恶性。而大约20%的针吸细胞学不能诊断结节的良恶性。一些特异性的分子生物标志物已经应用到甲状腺结节针吸细胞学的衍生检测中并取得了相当大的进展，提高了术前诊断率。

关键词: 甲状腺结节, 生物学标记, 活组织检查, 针吸

Abstract: The check methods of thyroid nodules include palpation, serum thyroid hormone and highfrequency ultrasound. When the diagnosis is difficult, fineneedle aspiration (FNA) is carried to differentiate benign and malignant nodules. In clinical practice, approximately 20% of FNAderived cytology reports can not meet the standard of benign or malignant. Some specific molecular biomarkers are applied to the derivative detection of FNA, which achieve considerable progress and improve the preoperative diagnostic rate.

Key words: Thyroid nodule, Biological markers, Biopsy, needle

谢传信, 王圣应. 细针穿刺联合分子生物标志物在甲状腺结节诊断中的研究进展[J]. 国际肿瘤学杂志, 2013, 40(11): 836-839.

XIE Chuan-Xin, WANG Sheng-Ying. Fine needle aspiration combined with molecular biomarkers in the diagnosis of thyroid nodules[J]. Journal of International Oncology, 2013, 40(11): 836-839.

参考文献

［1］ Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract, 2010, 16（Suppl 1）:1-43. ［2］ Cooper DS, Doherty GM, Haugen BR, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11):1167-1214. ［3］ Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid, 2009, 19(11):1159-1165. ［4］ Wang CCC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid, 2011, 21(3):243-251. ［5］ Saleh HA, Feng J, Tabassum F, et al. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal, 2009, 6(1):18. ［6］ Cochand-Priollet B, Dahan H, Laloi-Michelin M, et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid, 2011, 21(10):1067-1073. ［7］ Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol, 2010, 322(1-2): 29-37. ［8］ Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab, 2011, 96(7):2016-2026. ［9］ Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab, 2011, 96(11): 3390-3397. ［10］ Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New Engl J Med, 2012, 367(8):705-715. ［11］ Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using highdimensionality genomic data. J Clin Endocrinol Metab, 2010, 95(12):5296-5304. ［12］ Haugen BR, Baloch ZW, Chudova D, et al. Development of a novel molecular classifier to accurately identify benign thyroid nodules in patients with indeterminate FNA cytology. Presented at the 14th International Thyroid Congress. Paris, France: 2010:11-16. ［13］ He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A, 2005,102(52):19075-19080. ［14］ Sheu SY, Grabellus F, Schwertheim S, et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer, 2009, 102(2):376-382. ［15］ Mazeh H, Mizrahi I, Halle D, et al. Development of a microRNAbased molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid, 2011, 21(2):111-118. ［16］ de la Chapelle A, Jazdzewski K. MicroRNAs in thyroid cancer. J Clin Endocrinol Metab, 2011, 96(11):3326-3336. ［17］ Starega-Roslan J, Krol J, Koscianska E, et al. Structural basis of microRNA length variety. Nucleic Acids Res, 2011, 39(1):257-268. ［18］ Chen YT, Kitabayashi N, Zhou XK, et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol, 2008, 21(9):1139-1146. ［19］ Milas M, Shin J, Gupta M, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg, 2010, 252(4):643-651. ［20］ Milas M, Barbosa GF, Mitchell J, et al. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol, 2009, 16(2):473-480.

[1]	凡梦思, 陆雅萍, 闫莉. 子宫内膜癌前哨淋巴结假阴性患者的临床病理特征分析[J]. 国际肿瘤学杂志, 2023, 50(5): 274-279.
[2]	宋彤骏, 邓睿, 费蕾, 雷金华, 曹风军. CT与超声引导下经皮肺或胸膜病变穿刺活检的有效性和安全性比较[J]. 国际肿瘤学杂志, 2022, 49(9): 526-531.
[3]	张敏, 周丽娜, 徐姗姗, 陈骏. 肿瘤免疫治疗相关预测生物标志物研究进展[J]. 国际肿瘤学杂志, 2020, 47(8): 487-491.
[4]	刘虹, 吴剑, 李宏江, 羊晓勤. 微小RNA在乳腺癌检测、治疗、耐药及预后中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(12): 756-760.
[5]	王欢,蒋海萍,高源,徐农,俞雄飞. 抗PD-1/PD-L1免疫治疗生物标志物研究进展[J]. 国际肿瘤学杂志, 2019, 46(1): 40-44.
[6]	刘厚杰, 万经海. 脑膜瘤恶性进展的分子机制[J]. 国际肿瘤学杂志, 2018, 45(8): 494-498.
[7]	王拓，李桂香. 循环肿瘤DNA检测在放疗中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(6): 352-354.
[8]	黄灿，陈秋燕，左菲菲，彭川，钟绍斌，麦海强，陈明远，邹如海. 淋巴结EBV-DNA检测在鼻咽癌颈淋巴结转移中的诊断价值[J]. 国际肿瘤学杂志, 2018, 45(3): 143-147.
[9]	王阿香，高全立. PD-1/PD-L1抑制剂疗效预测的生物标志物[J]. 国际肿瘤学杂志, 2018, 45(12): 751-755.
[10]	王燕军，康晓静. 黑色素瘤的生物标志物[J]. 国际肿瘤学杂志, 2018, 45(1): 59-.
[11]	彭琦, 陈辅萍, 党晓敏. 长非编码RNA SBF2-AS1在非小细胞肺癌中的表达和临床意义[J]. 国际肿瘤学杂志, 2017, 44(8): 652-655.
[12]	申骏龙,刘全海,刘莉,南淑良,程永毅,周建成. 改良13点前列腺穿刺活检在前列腺癌诊断中的应用 [J]. 国际肿瘤学杂志, 2017, 44(12): 907-910.
[13]	崔金元，陶凯雄. 生物标志物在阻断PD-1/PD-L1通路治疗肿瘤中的预测性作用[J]. 国际肿瘤学杂志, 2016, 43(6): 452-454.
[14]	岳进,苏丽萍. 18FFDG PET/CT对淋巴瘤骨髓浸润的诊断及预后评估[J]. 国际肿瘤学杂志, 2016, 43(5): 395-397.
[15]	林建英, 杨熙鸿, 郭海鹏, 徐漫彬, 许少伟, 彭汉伟. 近红外线吲哚氰绿荧光显像法在cN₀口腔癌前哨淋巴结活检中的应用[J]. 国际肿瘤学杂志, 2016, 43(2): 86-.